| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/22/2002 | DE10055857A1 Neue pharmazeutische Depotformulierung New pharmaceutical depot formulation |
| 08/22/2002 | CA2438551A1 Ppar agonists |
| 08/22/2002 | CA2438501A1 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 08/22/2002 | CA2438492A1 Proliferative activator receptor (ppar) compounds |
| 08/22/2002 | CA2438215A1 Putative human enzymes |
| 08/22/2002 | CA2437967A1 Novel ophthalmic compositions |
| 08/22/2002 | CA2437890A1 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 08/22/2002 | CA2437873A1 Neurotonin and use thereof |
| 08/22/2002 | CA2437823A1 Acrochordon alleviation |
| 08/22/2002 | CA2437811A1 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 08/22/2002 | CA2437768A1 Targetted anti-tumor drug delivery systems |
| 08/22/2002 | CA2437731A1 A medicinal composition and use comprising turmeric extract for smoke detoxification |
| 08/22/2002 | CA2437333A1 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin |
| 08/22/2002 | CA2437118A1 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 08/22/2002 | CA2436452A1 A compound and method of treatment for fungal pathologies of the oral cavity |
| 08/22/2002 | CA2436259A1 Compounds effecting neuron remodeling and assays for same |
| 08/22/2002 | CA2434835A1 Novel modified released formulation |
| 08/22/2002 | CA2434641A1 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| 08/22/2002 | CA2434542A1 Novel modified release formulation |
| 08/22/2002 | CA2433843A1 Molecules for disease detection and treatment |
| 08/22/2002 | CA2430726A1 Isolated human transporter proteins, nucleic acid molecules encoding them and uses thereof |
| 08/22/2002 | CA2427112A1 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 08/21/2002 | EP1233063A2 Transgenic animals containing a dominant negative mutant form of the p85 subunit of pi-3 kinase |
| 08/21/2002 | EP1233023A1 Transcription factor and dna thereof |
| 08/21/2002 | EP1232756A1 Drugs, drinks or foods |
| 08/21/2002 | EP1232755A2 Anti-HIV agents |
| 08/21/2002 | EP1232284A1 Genomic polymorphism for predicting therapeutic response |
| 08/21/2002 | EP1232185A2 Methods of inhibiting metastasis |
| 08/21/2002 | EP1232180A1 Polypeptides derived from vitamin d nuclear receptor, and their uses in particular for screening vitamin d analogues |
| 08/21/2002 | EP1232178A2 Compositions and methods for regulating tumor-associated antigen expression |
| 08/21/2002 | EP1232177A2 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides |
| 08/21/2002 | EP1232173A1 Fusidic acid derivatives |
| 08/21/2002 | EP1232159A1 Beta-amyloid peptide inhibitors |
| 08/21/2002 | EP1231983A2 Treatment of subnormal bone mineral density |
| 08/21/2002 | EP1231939A2 Oncolytic combinations for the treatment of cancer |
| 08/21/2002 | EP1231938A2 Oncolytic combinations for the treatment of cancer |
| 08/21/2002 | EP1231937A2 Tr3-specific binding agents and methods for their use |
| 08/21/2002 | EP1231934A2 Methods of inhibiting atrophy or promoting hypertrophy |
| 08/21/2002 | EP1231927A2 Nontoxic vernix compositions and method of producing |
| 08/21/2002 | EP1231925A1 Method and composition for the treatment of adenoviral ocular infections |
| 08/21/2002 | EP1231924A2 Treatment of systemic lupus erythematosus (sle) with dehydroepiandrosterone |
| 08/21/2002 | EP1231923A1 Protease inhibitors |
| 08/21/2002 | EP1231913A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 08/21/2002 | EP1231910A2 Inhibitors of endo-exonuclease activity such as pentamidine for treating cancer |
| 08/21/2002 | EP1231907A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 08/21/2002 | EP1231887A2 Method and composition for the treatment of scars |
| 08/21/2002 | EP1231886A1 Topical skin composition |
| 08/21/2002 | EP1231877A1 Transdermal administration of huperzine |
| 08/21/2002 | EP0980251B1 Tissue factor for influencing blood vessel formation |
| 08/21/2002 | EP0956034B1 Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxyethyl)-rapamycin |
| 08/21/2002 | EP0771192B1 Use of anti-vegf agents in the treatment of endometriosis |
| 08/21/2002 | EP0637203B1 Regulation of the immune system |
| 08/21/2002 | CN1365395A Tenascin-C nucleic acid liqands |
| 08/21/2002 | CN1365363A thineopyranecarboxyamide derivatives |
| 08/21/2002 | CN1365293A Agents promoting the formation of skin basement, agents promoting the formation of artificial skin and process for producing artificial skin |
| 08/21/2002 | CN1365288A Method for detecting and killing epithelial cancer cells |
| 08/21/2002 | CN1365287A Pharmaceutical composition containing enantioners and lipase inhibitor |
| 08/21/2002 | CN1365284A Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
| 08/21/2002 | CN1365279A Preparations for reducing oxygen consumption during physical efforts |
| 08/21/2002 | CN1089239C Pyrimidine nucleotide precursors of treatment of animal inflammations and tissue damages |
| 08/20/2002 | US6437110 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 08/20/2002 | US6437004 Treatment of skin damage using olive oil polyphenols |
| 08/20/2002 | US6436997 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 08/20/2002 | US6436993 Synergistic mixtures of retinoic acid receptor (rar) antagonists and steroid, thyroid or retinoid receptor agonists such as peroxisome proliferator activated receptors used to control cellular processes |
| 08/20/2002 | US6436989 Prodrugs of aspartyl protease inhibitors |
| 08/20/2002 | US6436977 Dosing regimens for lasofoxifene |
| 08/20/2002 | US6436975 Pharmaceutical compositions for ulcer |
| 08/20/2002 | US6436970 Compositions for the treatment of ARDS or IRDS containing 3-(cycloproplymethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamide and lung surfactant |
| 08/20/2002 | US6436969 Dialysis solutions and methods |
| 08/20/2002 | US6436962 Alpha 1a adrenergic receptor antagonists; relief from benign prostatic hyperplasia by less hindered urine flow by relaxing smooth muscle tissue; with a testosterone 5-alpha reductase inhibitor, finasteride; acute and chronic relief |
| 08/20/2002 | US6436950 Effective for the amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects; sodium metabisulfite, ascorbic acid, or sodium ascorbate reducing agent |
| 08/20/2002 | US6436944 Combination effective for the treatment of impotence |
| 08/20/2002 | US6436938 Combination treatment for depression |
| 08/20/2002 | US6436924 Useful for treating allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis; nonsedating antihistamines or salts, leukotriene d4 antagonist or 5-lipoxygenase inhibitor or flap protein antagonist |
| 08/20/2002 | US6436907 Adenovirus-medicated gene transfer to cardiac and vascular smooth muscle |
| 08/20/2002 | US6436903 Immunomodulating compounds comprising d-isomers of amino acids |
| 08/20/2002 | US6436686 Isolated microtubule motor protein having microtubule stimulated adenosine triphosphatase activity and having greater than 90% amino acid sequence identity to specified sequence as measured using sequence comparison algorithm |
| 08/20/2002 | US6436684 Isolated nucleic acid molecule consisting of selected nucleotide sequence encoding phenol sulfotransferase protein |
| 08/20/2002 | US6436670 Gene and uses therefor |
| 08/20/2002 | US6436642 Method of classifying a thyroid carcinoma using differential gene expression |
| 08/20/2002 | US6436637 Polynucleotide; expression vector; antiinflammatory agents; cell proliferative and apoptosis disorder treatment |
| 08/20/2002 | US6436629 Modulating angiogenesis |
| 08/20/2002 | US6436431 Fortified rice bran food product and method for promoting cardiovascular health |
| 08/20/2002 | US6436430 Self-emulsifying compositions for drugs poorly soluble in water |
| 08/20/2002 | US6436386 Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
| 08/20/2002 | US6436366 Detecton, treatment and monitoring the patient with poor wound healing ability due to diabetes based on measurement of the breakdown product of nitric oxide (no) in specimens taken from the patient under controlled conditions |
| 08/20/2002 | US6435873 Medication delivery devices |
| 08/20/2002 | CA2335397C A method for screening compounds for their potential to inhibit neoplasia and pharmaceutical compositions containing such compounds |
| 08/20/2002 | CA2266183C Herbal composition for treatment of bronchitis and respiratory disorders with anti cancer properties and process for preparing same |
| 08/20/2002 | CA2250263C Human netrin-1 |
| 08/20/2002 | CA2238283C Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
| 08/20/2002 | CA2045077C Anti-epileptics |
| 08/15/2002 | WO2002063308A2 Prediction of wound healing by urinary nitrate assay |
| 08/15/2002 | WO2002063038A1 Method for identifying compounds modulating reverse cholesterol transport |
| 08/15/2002 | WO2002063008A2 Intracellular signaling molecules |
| 08/15/2002 | WO2002063006A2 Receptors and membrane-associated proteins |
| 08/15/2002 | WO2002063005A2 Lipid-associated molecules |
| 08/15/2002 | WO2002063004A2 G-protein coupled receptors |
| 08/15/2002 | WO2002062994A1 Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals |
| 08/15/2002 | WO2002062978A1 Method and composition for in situ metabolizing of glutathione and nad |